Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Cash from Financing Activities: 2015-2025

Historic Cash from Financing Activities for Syndax Pharmaceuticals (SNDX) over the last 11 years, with Sep 2025 value amounting to $6.3 million.

  • Syndax Pharmaceuticals' Cash from Financing Activities rose 102.65% to $6.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $355.2 million, marking a year-over-year increase of 34.32%. This contributed to the annual value of $353.4 million for FY2024, which is 33.78% up from last year.
  • Syndax Pharmaceuticals' Cash from Financing Activities amounted to $6.3 million in Q3 2025, which was up 1,039.38% from $551,000 recorded in Q2 2025.
  • In the past 5 years, Syndax Pharmaceuticals' Cash from Financing Activities ranged from a high of $347.4 million in Q4 2024 and a low of -$13.5 million during Q3 2022.
  • Over the past 3 years, Syndax Pharmaceuticals' median Cash from Financing Activities value was $2.2 million (recorded in 2024), while the average stood at $56.8 million.
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first plummeted by 893.26% in 2022, then soared by 344.17% in 2023.
  • Quarterly analysis of 5 years shows Syndax Pharmaceuticals' Cash from Financing Activities stood at $109.8 million in 2021, then soared by 48.94% to $163.5 million in 2022, then skyrocketed by 58.09% to $258.5 million in 2023, then skyrocketed by 34.41% to $347.4 million in 2024, then skyrocketed by 102.65% to $6.3 million in 2025.
  • Its Cash from Financing Activities stands at $6.3 million for Q3 2025, versus $551,000 for Q2 2025 and $930,000 for Q1 2025.